- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

H.R. 4132
U.S. House•In House Committee
Summary
H.R. 4132, the Prescription Information Modernization Act of 2025, was introduced in the House on Jun 25, 2025 by Rep. Diana Harshbarger (R) with 16 co-sponsors. It was referred to Energy And Commerce, and last saw action on Jun 25, 2025: Referred to the House Committee on Energy and Commerce.
Record
Text
H.R. 4132 has 16 co-sponsors.
hb4132/introduced-in-house.txt119 HR 4132 IH: Prescription Information Modernization Act of 2025U.S. House of Representatives2025-06-25text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.I 119th CONGRESS 1st Session H. R. 4132 IN THE HOUSE OF REPRESENTATIVES June 25, 2025 Mrs. Harshbarger (for herself, Ms. Sherrill , Mr. Valadao , Mr. Davis of North Carolina , Mr. Calvert , Ms. Ross , Ms. Letlow , Mr. Peters , Mr. Schneider , Mr. Womack , and Mr. Tonko ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILLTo provide for digital communication of prescribing information for drugs (including biological products), and for other purposes.1.Short titleThis Act may be cited as the Prescription Information Modernization Act of 2025 .2.Digital communication of FDA-approved prescribing information for drugs (including biological products)(a)In generalSection 502(f) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352(f) ) is amended by adding at the end the following: Required prescribing information for drugs subject to section 503(b)(1) may be made available solely by electronic means provided that the labeling complies with all applicable requirements of law, that the manufacturer affords prescribers and dispensers the opportunity to elect to also continue to receive all such information in paper form, or to request paper labeling on an as-needed basis, and after such request, and that the manufacturer promptly provides the requested information without additional cost. .(b)Rulemaking(1)In generalNot later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services shall issue final regulations to—(A)implement the amendment made by subsection (a); and(B)provide instructions on how health care professionals can receive paper copies of prescribing information directly from the manufacturer or distributor if desired.(2)Economic impactsThe Secretary of Health and Human Services shall design the regulations required by paragraph (1) so as to minimize the adverse economic impacts of such regulations on prescribers and dispensers.(c)Public workshopNot later than 2 years after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall hold a public workshop with relevant stakeholders to discuss how to continue to optimize the format, accessibility, and usability of prescribing information.(d)Effective dateThe amendment made by subsection (a) shall apply with respect to drugs introduced or delivered for introduction into interstate commerce on or after the sooner of—(1)the date that is 2 years after the date of the enactment of this Act; or(2)the effective date of the final regulations promulgated to implement such amendment.(e)DefinitionIn this section, the term drug has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ).
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-06-25
- Passed House
- Passed Senate
- Conference
- To President
- Became Law
To provide for digital communication of prescribing information for drugs (including biological products), and for other purposes.
Sponsors
Rep. Diana Harshbarger (R) sponsors H.R. 4132, and 16 members have co-sponsored it, 10 of them from the day it was introduced.

Rep. · R–TN-1 · Sponsor
Introduced Jun 25, 2025

Rep. · R–CA-41 · Co-sponsor
Joined Jun 25, 2025 · Original

Rep. · D–NC-1 · Co-sponsor
Joined Jun 25, 2025 · Original

Rep. · R–LA-5 · Co-sponsor
Joined Jun 25, 2025 · Original

Rep. · D–CA-50 · Co-sponsor
Joined Jun 25, 2025 · Original

Rep. · D–NC-2 · Co-sponsor
Joined Jun 25, 2025 · Original

Rep. · D–IL-10 · Co-sponsor
Joined Jun 25, 2025 · Original

Rep. · D–NJ-11 · Co-sponsor
Joined Jun 25, 2025 · Original

Rep. · D–NY-20 · Co-sponsor
Joined Jun 25, 2025 · Original

Rep. · R–CA-22 · Co-sponsor
Joined Jun 25, 2025 · Original
Committees
H.R. 4132 went before 1 committee: Energy and Commerce.
Actions
H.R. 4132 has taken 2 actions since Jun 25, 2025.
| Chamber | Action | |||
|---|---|---|---|---|
Jun 25, 2025 | House | Introduced in House | ||
Jun 25, 2025 | House | Referred to the House Committee on Energy and Commerce.Energy and Commerce Committee |
Votes
H.R. 4132 has not gone to a roll call.
Related bills
2 bills are related to H.R. 4132.
S 2027Prescription Information Modernization Act of 2025Jun 11, 2025 · Read twice and referred to the Committee on Health, Education, Labor, and Pensi… · Related bill
S 5242Prescription Information Modernization Act of 2026Aug 4, 2026 · Read twice and referred to the Committee on Health, Education, Labor, and Pensi… · Related billTitles
H.R. 4132 goes by 3 titles, 1 of them short titles.
- Prescription Information Modernization Act of 2025 — Display Title
- Prescription Information Modernization Act of 2025 — Short Title(s) as Introduced
- To provide for digital communication of prescribing information for drugs (including biological products), and for other purposes. — Official Title as Introduced
Lobbying
9 clients hired 9 firms and 57 registered lobbyists who named H.R. 4132 in 30 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Trade (domestic/foreign), Health Issues, Pharmacy, Copyright/Patent/Trademark, Medicare/Medicaid, Taxation/Internal Revenue Code, Budget/Appropriations, Financial Institutions/Investments/Securities.
Clients
Who paid to be heard, by how many filings named the bill.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| CENCORA, INC. | — | District of Columbia | 1 | 5 | — |
| PRINTING UNITED ALLIANCE | — | Virginia | 1 | 5 | — |
| VIATRIS INC | — | Pennsylvania | 1 | 5 | — |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | — | District of Columbia | 1 | 4 | — |
| ASTRAZENECA PHARMACEUTICALS LP | — | Delaware | 1 | 3 | — |
| GSK (FKA GLAXOSMITHKLINE INC.) | — | District of Columbia | 1 | 3 | — |
| COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE | — | District of Columbia | 1 | 2 | — |
| HEALTHCARE INSTITUTE OF NEW JERSEY | — | New Jersey | 1 | 2 | — |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | — | District of Columbia | 1 | 1 | — |
Firms
Registrants who filed on the bill, by filings.
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 57.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| ANNE WILSON | 1 | 1 | 5 |
| DARRELL ROGERS | 1 | 1 | 5 |
| KATHARINE HAYES | 1 | 1 | 5 |
| LISBETH LYONS | 1 | 1 | 5 |
| PETER WALLACE | 1 | 1 | 5 |
| SHELLY MUI-LIPNIK | 1 | 1 | 5 |
| VIVIENNE MITCHELL | 1 | 1 | 5 |
| ILHAAM JAFFER | 1 | 1 | 4 |
| JOHN MURPHY | 1 | 1 | 4 |
| KARIN HESSLER | 1 | 1 | 4 |
| PETER KELBEL | 1 | 1 | 4 |
| WILL DENT | 1 | 1 | 4 |
| ART MOTTA | 1 | 1 | 3 |
| CAROLINE QUAT | 1 | 1 | 3 |
| DAVID MARIN | 1 | 1 | 3 |
| EMILY MACE | 1 | 1 | 3 |
| HARMEET DHILLON | 1 | 1 | 3 |
| KATIE JONES | 1 | 1 | 3 |
| LIAM MACDONALD | 1 | 1 | 3 |
| LISA LANGENDERFER | 1 | 1 | 3 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 second_quarter | $7.6M | 2nd Quarter - Report |
| ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | 2026 first_quarter | $2.3M | 1st Quarter - Report |
| CENCORA, INC. | CENCORA, INC. | 2025 fourth_quarter | $1.9M | 4th Quarter - Report |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | 2025 third_quarter | $1.7M | 3rd Quarter - Report |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | 2025 second_quarter | $1.5M | 2nd Quarter - Report |
| ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | 2025 third_quarter | $1.4M | 3rd Quarter - Report |
| CENCORA, INC. | CENCORA, INC. | 2026 first_quarter | $1.2M | 1st Quarter - Report |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2025 fourth_quarter | $1.2M | 4th Quarter - Report |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2026 first_quarter | $840K | 1st Quarter - Report |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | 2025 fourth_quarter | $810K | 4th Quarter - Report |
| CENCORA, INC. | CENCORA, INC. | 2025 second_quarter | $760K | 2nd Quarter - Report |
| CENCORA, INC. | CENCORA, INC. | 2025 third_quarter | $680K | 3rd Quarter - Report |
| ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | 2025 fourth_quarter | $670K | 4th Quarter - Report |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2025 second_quarter | $650K | 2nd Quarter - Report |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2025 third_quarter | $640K | 3rd Quarter - Report |
| VIATRIS INC | VIATRIS INC. | 2025 third_quarter | $640K | 3rd Quarter - Report |
| VIATRIS INC | VIATRIS INC. | 2025 second_quarter | $590K | 2nd Quarter - Report |
| CENCORA, INC. | CENCORA, INC. | 2026 second_quarter | $510K | 2nd Quarter - Report |
| VIATRIS INC | VIATRIS INC. | 2026 first_quarter | $490K | 1st Quarter - Report |
| VIATRIS INC | VIATRIS INC. | 2025 fourth_quarter | $490K | 4th Quarter - Report |
Classification
The Congressional Research Service files H.R. 4132 under Health, one of its 31 policy areas.
CRS Subjects
CRS assigns every bill one policy area from its 31; H.R. 4132’s is Health.
hr4132/policy-areas.txtConstitutional authority
The clause the sponsor cites as Congress’s power to enact H.R. 4132, as entered in the Congressional Record.
[Congressional Record Volume 171, Number 109 (Wednesday, June 25, 2025)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mrs. HARSHBARGER:H.R. 4132.Congress has the power to enact this legislation pursuantto the following:Article I; Section 8 of the United States Constitution[Page H2970]
Source: congress.gov · legiscan.com